ISSN:0378-584X    

DOI:10.1159/000217425

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000217426

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger

摘要:

Background: Acute promyelocytic leukemia (APL) is frequently associated with disseminated coagulopathy (DIC), causing a high incidence of fatal bleeding complications despite induction chemotherapy administered immediately after diagnosis. APL is cytogenetically characterized by the translocation t(15;17) involving the region of the retinoic receptor α gene. In vitro all trans retinoic acid (ATRA) exhibits a differentiation-inducing and antiproliferative capacity on APL-cell lines. Similar effects were observed when APL-patients treated with ATRA achieved complete remission. Patients and Methods: We have treated five patients with APL with 45 mg/m2 all trans retinoic acid for 90 to 106 days. Results: Signs of DIC, seen in four patients, improved within a few days of treatment. Hyperleukocytosis developed in two patients. ATRA side effects (dryness of skin, alopecia, bone pain) were mild and improved as treatment continued. All patients achieved complete hematological and cytogenetic remission within five to twelve weeks. Conclusion: ATRA therapy for APL is safe and highly effective, but further approaches for remission maintenance are required.

ISSN:0378-584X    

DOI:10.1159/000217331

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger

摘要:

Background: Hematologic growth factors may allow those intensification of chemotherapy possibly leading to an improvement of treatment results in high grade malignant non-Hodgkin’s lymphomas. In the present study the possibility of reducing the time intervals between treatment cycles of chemotherapy was examined. Patients and Methods: In 24 patients with high grade malignant lymphomas intervals between VIM/CHOP chemotherapy cycles were reduced from the original 21 to 17 and even 14 days. G-CSF 5 μg/kg was administered s.c. for ten days after each treatment cycle. Results: It was possible to apply chemotherapy in the scheduled, reduced interval in more than 80% of the cycles. Major side effects of G-CSF treatment were observed in only two patients experiencing bone pain. Other toxicity was chemotherapy related and seldom severe. Conclusions: With the administration of G-CSF, treatment intervals of VIM/CHOP chemotherapy can safely be reduced. Whether this will lead to better treatment results needs further examination.

ISSN:0378-584X    

DOI:10.1159/000217332

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger

摘要:

Background: In prior pilot studies Interferon-alpha2b (IFN-alpha) was shown to be effective in B-cell type chronic lymphocytic leukemia (B-CLL). Therefore, the benefit of an IFN-alpha-therapy in early phase B-CLL is assessed with respect to freedom from progression and long term survival in a randomized multicenter study. Material and methods: Patients with early phase B-CLL (Binet A) and high risk for progression (diffuse bone marrow infiltration plus serum level of thymidinkinase > 5 U/l plus/or lymphocyte doubling time < 12 months) are randomized into an ΓFN-treat-ment group (arm A) or a watch and wait group (arm B). Patients who do not share the risk parameters are documented in another watch and wait arm C Dosage of IFN-alpha is 3 x 5 Mill. IE per week. Results: Out of 14 evaluable patients im arm A two patients achieved a complete remission (normalization of blood cell counts, no lymph nodes palpable) and three patients attained a partial remission. Three patients have stable disease, and one out of four patients with progressive disease was in need of chemotherapy. Ten out of 15 evaluable patients in arm B have stable disease, but five others had progressive disease with four patients in need of chemotherapy. None of the 24 evaluable patients in arm C had progressive disease with need of chemotherapy. Conclusion: These preliminary results seem to prove the validity of the risk parameters and show the possible benefit of an IFN-treatment in early phase B-CLL at high risk for progression.

ISSN:0378-584X    

DOI:10.1159/000217333

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000217334

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000217335

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000217336

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000217337

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger